Bolt Biotherapeutics, Inc.
BOLTNasdaq
$4.42
↑ +5.5%Jul 17 close · end-of-day
Price
1Y↓ -23.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$7.4M
Enterprise Value
-$15.5M
P/E
—
P/S
1.1
P/B
0.4
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$6.5M
Net Income (TTM)
-$29.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-486.2%
Net Margin
-455.1%
ROE
-149.2%
ROIC
—
Debt / Equity
—
Net Cash
$22.9M
Return 1Y
-23.0%
Company profile
Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.
- CEO
- Randall C. Schatzman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- California
- Website
- boltbio.com
Management & directors
- Nemec SarahSenior VP, Finance and PAO
- Quinn William P.President, CEO and CFO
- Yonehiro GrantChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
BOLT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$26,000.00↓ -97.9%
Diluted EPS-$4.31↓ -25.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $231,000.00 | $1.3M | $5.7M | $7.9M | $7.7M | $7.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$49.2M | -$92.8M | -$90.3M | -$76.2M | -$73.0M | -$36.1M |
| Net income | -$60.7M | -$98.6M | -$88.1M | -$69.2M | -$63.1M | -$33.4M |
| Diluted EPS | — | -$2.97 | -$2.36 | -$1.83 | -$33.06 | -$17.85 |
| Operating cash flow | -$47.3M | -$57.1M | -$76.5M | -$69.5M | -$61.3M | -$39.9M |
| Free cash flow | -$50.6M | -$59.4M | -$78.5M | -$69.7M | -$61.3M | -$39.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -21290.9% | -7364.1% | -1576.6% | -967.4% | -949.9% | -469.3% |
| Net margin | -26289.2% | -7824.7% | -1537.8% | -878.6% | -820.8% | -433.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.1M | $0.00 | $1.2M | $1.8M | $2.2M | $2.5M | $26,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.6M | -$16.4M | -$16.9M | -$12.1M | -$9.2M | -$7.7M | -$7.1M | -$7.6M |
| Net income | -$21.2M | -$15.2M | -$15.9M | -$11.0M | -$8.6M | -$7.1M | -$6.6M | -$7.2M |
| Diluted EPS | -$11.12 | -$7.93 | -$13.73 | -$5.76 | -$4.46 | -$3.72 | -$3.91 | -$4.31 |
| Operating cash flow | -$16.1M | -$14.0M | -$14.4M | -$13.4M | -$9.6M | -$9.7M | -$7.2M | -$8.0M |
| Free cash flow | -$16.1M | -$14.0M | -$14.4M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1772.3% | -1441.1% | — | -991.4% | -510.5% | -355.1% | -283.4% | -29234.6% |
| Net margin | -1662.4% | -1330.1% | — | -903.4% | -474.6% | -329.4% | -265.2% | -27861.5% |
Company news
May 12, 2026
Mar 12, 2026
- 129d agoBolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimatesfinance.yahoo.com
- 129d agoBolt Biotherapeutics Inc.: Q4 Earnings Snapshotfinance.yahoo.com
- 130d agoBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Updatefinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-12-05 | Quinn William P.· President, CEO and CFO | Buy | 125 | $4.61 | $575.88 | filing |
| 2025-12-05 | Nemec Sarah· Senior VP, Finance and PAO | Buy | 125 | $4.61 | $575.88 | filing |
| 2025-10-22 | Nemec Sarah· Senior VP, Finance and PAO | Award | 23,000 | $0.00 | $0.00 | filing |
| 2025-10-22 | Yonehiro Grant· Chief Operating Officer | Award | 30,000 | $0.00 | $0.00 | filing |
| 2025-10-22 | Quinn William P.· President, CEO and CFO | Award | 40,000 | $0.00 | $0.00 | filing |
Latest 5 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.